Evidence map›Paper›PMID 22264047›Full record

ReviewCurrent HIV research2012

Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development.

Colleen R Eade, Matthew P Wood, Alexander M Cole

Abstract readReview
In one paragraph

Review in Current HIV research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Peptide-Based Antiviral Drugs.Advances in experimental medicine and biology · 2021
    Article
  3. Antiviral Activities of Human Host Defense Peptides.Current medicinal chemistry · 2020
    Review
  4. Article
  5. Comparative Analysis of the Integument Transcriptomes betweenInternational journal of molecular sciences · 2018
    Article
  6. Antiviral mechanisms of human defensins.Journal of molecular biology · 2013
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Colleen R EadeDepartment of Molecular Biology and Microbiology, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32816, USA. acole@mail.ucf.edu
Matthew P Wood
Alexander M Cole

Funding

RT Inhibitor CSIC and Entry Inhibitor Retrocyclin RC101 as MicrobicidesU19AI082623 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARNIAK, MICHAEL A · 2009 to 2012
$7.3M
Retrocyclins: Circular Defensins Active Against HIV-1R01AI052017 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI COLE, ALEXANDER MICHAEL · 2002 to 2010
$3.0M
Aminoglycoside microbicides restore natural expression of anti-HIV-1 retrocyclinsR33AI082693 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI COLE, ALEXANDER MICHAEL · 2011 to 2013
$1.4M
Aminoglycoside microbicides restore natural expression of anti-HIV-1 retrocyclinsR21AI082693 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI COLE, ALEXANDER MICHAEL · 2009 to 2010
$392k
Retrocyclins: circular defensins active against HIV-1R56AI052017 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI COLE, ALEXANDER MICHAEL · 2011 to 2011
$383k
NIAID NIH HHS AI052017NIAID NIH HHS AI082623NIAID NIH HHS AI082693NIAID NIH HHS R01 AI052017NIAID NIH HHS R21 AI082693NIAID NIH HHS R33 AI082693NIAID NIH HHS R56 AI052017NIAID NIH HHS U19 AI082623
6 · The paper itself

Abstract

Despite advances in the treatment of HIV infection, heterosexual transmission of HIV remains high, and vaccines to prevent HIV acquisition have been unfruitful. Vaginal microbicides, on the other hand, have demonstrated considerable potential for HIV prevention, and a variety of compounds have been screened for their activity and safety as anti-HIV microbicides. Among these are the naturally occurring host defense peptides, small peptides from diverse lineages with intrinsic antiviral activity. Naturally occurring host defense peptides with anti-HIV activity are promising candidates for vaginal microbicide development. Their structural variance and accompanying mechanistic diversity provide a wide range of inhibitors whose antiviral activity can be exerted at nearly every stage of the HIV lifecycle. Additionally, peptide modification has been explored as a method for improving the anti-HIV activity of host defense peptides. Structure- and sequence-based alterations have achieved varying success in improving the potency and specificity of anti-HIV peptides. Overall, peptides have been discovered or engineered to inhibit HIV with therapeutic indices of > 1000, encouraging their advancement toward clinical trials. Here we review the naturally occurring anti-HIV host defense peptides, demonstrating their breadth of mechanistic diversity, and exploring approaches to enhance and optimize their activity in order to expedite their development as safe and effective anti-HIV vaginal microbicides.

Indexed as

Anti-Infective Agents, LocalAnti-Retroviral AgentsDefensinsDrug DesignHIV-1HIV InfectionsHumansPeptidesAnti-Infective Agents, LocalAnti-Retroviral AgentsDefensinsPeptides

Identifiers

PMID22264047
PMCPMC4270272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.